Trial Profile

Phase 2a Open-Label Basket Study to Evaluate Safety and Pharmacokinetics of INF904, an Oral C5aR1 Inhibitor, in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2025 According to an InflaRx media release, the Phase 2a study is progressing toward completion of the 4-week post-treatment observation period, with final results planned for presentation at major scientific meetings, and the company also intends to host a Capital Markets Event to highlight the potential of INF904.
10 Nov 2025 According to an InflaRx media release, company will host a webcast to discuss the topline data from this trial today at 8:00 AM EST / 2:00 PM CET
10 Nov 2025 Results presented in an InflaRx media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com